EULAV Asset Management purchased a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 19,400 shares of the company's stock, valued at approximately $1,668,000.
A number of other large investors have also recently bought and sold shares of PBH. Kayne Anderson Rudnick Investment Management LLC acquired a new position in Prestige Consumer Healthcare during the 4th quarter worth approximately $84,932,000. Raymond James Financial Inc. acquired a new position in Prestige Consumer Healthcare during the 4th quarter worth approximately $42,593,000. Norges Bank acquired a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at approximately $40,009,000. Bessemer Group Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 10,053.1% in the 4th quarter. Bessemer Group Inc. now owns 295,050 shares of the company's stock valued at $23,041,000 after buying an additional 292,144 shares during the last quarter. Finally, Natixis Advisors LLC boosted its holdings in shares of Prestige Consumer Healthcare by 1,335.1% in the 4th quarter. Natixis Advisors LLC now owns 209,246 shares of the company's stock valued at $16,340,000 after buying an additional 194,665 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.
Analyst Ratings Changes
Several research firms have recently commented on PBH. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Wall Street Zen upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of "Moderate Buy" and an average price target of $93.33.
Read Our Latest Analysis on Prestige Consumer Healthcare
Prestige Consumer Healthcare Price Performance
NYSE:PBH traded down $1.05 during trading hours on Monday, hitting $78.93. The company's stock had a trading volume of 359,188 shares, compared to its average volume of 306,647. The stock has a fifty day simple moving average of $84.17 and a 200-day simple moving average of $82.43. The company has a market capitalization of $3.90 billion, a P/E ratio of 18.40, a PEG ratio of 2.40 and a beta of 0.43. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.20 and a quick ratio of 2.82. Prestige Consumer Healthcare Inc. has a twelve month low of $64.94 and a twelve month high of $90.04.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The business had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. During the same period last year, the firm posted $1.02 earnings per share. Prestige Consumer Healthcare's revenue was up 7.0% compared to the same quarter last year. On average, analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.
Prestige Consumer Healthcare Profile
(
Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Read More

Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.